Premium
The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine‐induced dopaminergic deficits
Author(s) -
Volz Trent J.,
Hanson Glen R.,
Fleckenstein Annette E.
Publication year - 2007
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.04419.x
Subject(s) - methamphetamine , dopamine , dopaminergic , monoamine neurotransmitter , vesicular monoamine transporter , neuroscience , dopamine transporter , vesicular monoamine transporter 2 , chemistry , pharmacology , medicine , biology , serotonin , receptor , biochemistry
Amphetamine (AMPH) and methamphetamine (METH) are members of a collection of phenethylamine psychostimulants that are commonly referred to collectively as “amphetamines.” Amphetamines exert their effects, in part, by affecting neuronal dopamine transport. This review thus focuses on the effects of AMPH and METH on the plasmalemmal dopamine transporter and the vesicular monoamine transporter‐2 in animal models with a particular emphasis on how these effects, which may vary for the different stereoisomers, contribute to persistent dopaminergic deficits.